Lena Claesson Welsh

Title: The Innovative Contributions of Lena Claesson Welsh

Introduction

Lena Claesson Welsh is a notable inventor based in Uppsala, Sweden. She has made significant contributions to the field of biotechnology, particularly in the development of biologically active polypeptides. Her work focuses on anti-angiogenic properties, which have important implications for medical research and treatment.

Latest Patents

Lena Claesson Welsh holds a patent for an invention titled "Endogenous peptide and active subfragments thereof." This invention relates to a substantially pure biologically active consecutive anti-angiogenic polypeptide derived from the central region of human Histidine Rich Glycoprotein (HRGP). The polypeptide exhibits potential endogenous, naturally occurring subfragments of human HRGP, which possess similar anti-angiogenic activities as the mature protein. The invention also encompasses one or more new biologically active subfragments of human HRGP, all characterized by their anti-angiogenic activity. One of the active subfragments is referred to as Pep2, and the invention includes anti-angiogenic subfragments derived from Pep2, including a newly identified minimal functional entity.

Career Highlights

Lena Claesson Welsh is associated with Innoventus Project AB, where she continues to advance her research and innovations. Her work has garnered attention for its potential applications in therapeutic settings, particularly in combating diseases related to abnormal blood vessel growth.

Collaborations

Lena collaborates with Anna-Karin Olsson, who is also a key figure in her research endeavors. Together, they contribute to the advancement of knowledge in their field.

Conclusion

Lena Claesson Welsh's innovative work in the development of anti-angiogenic polypeptides highlights her significant role in biotechnology. Her contributions are paving the way for future advancements in medical treatments.